Effect of growth factors in combination with injectable silicone resin particles on the biological activity of dermal fibroblasts: a preliminary in vitro study.
Injections of silicone fluid have been clinically evaluated to treat and prevent foot ulcers due to diminished plantar fat-pad in neuropathic diabetics. The objective of this study was to determine preliminary in vitro effects of an injectable form of silicone resin particles in combination with growth factors to determine the suitability of this potential therapy for prevention of diabetic foot ulcers. Basic fibroblast growth factor (bFGF), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF-BB) were added to monolayer culture along with silicone resin particles (12 microm average diameter). Growth factors were also combined as follows: bFGF+PDGF-BB, EGF+PDGF-BB, and bFGF+EGF. Growth factors alone and in combination increased fibroblast proliferation, but the presence of particles did not significantly affect cellular proliferation. The addition of particles significantly increased fibronectin production 117% in the control group and 151% in the PDGF only group. Collagen production was increased with exposure to EGF and growth factor combinations, but the presence of particles did not lead to any significant differences, except an 81% increase in the bFGF group. These preliminary results suggest that a combination of PDGF and bFGF may be effective in stimulating proliferation and matrix production around injectable silicone resin particles to generate a fibrous tissue pad to alleviate the abnormal distribution of high pressures that contribute to diabetic foot ulcer formation.
Jennings
Jessica A
JA
Department of Biomedical Engineering, The University of Memphis, Memphis, Tennessee 38152, USA. jjnnings@memphis.edu
Crews
Robert M
RM
Robinson
Joycelyn
J
Richelsoph
Kelly
K
Cole
Judith A
JA
Bumgardner
Joel D
JD
Yang
Yunzhi
Y
Haggard
Warren O
WO
D000077214:Becaplermin; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000096:biosynthesis; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005346:Fibroblast Growth Factors / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D005353:Fibronectins / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D008855:Microscopy, Electron, Scanning; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D012828:Silicones; D012867:Skin / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure
D005353:Fibronectins; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012828:Silicones; D000077214:Becaplermin; D005346:Fibroblast Growth Factors; D004815:Epidermal Growth Factor; D003094:Collagen